Enlivex Therapeutics (ENLV) to review Phase IIa knee osteoarthritis topline data in August webinar

Rhea-AI Filing Summary

Enlivex Therapeutics Ltd. filed a Form 6-K noting it will host a webinar on August 18, 2025, at 8:00 Eastern Time. During the event, the company plans to present and discuss 3‑month topline results from the Phase IIa stage of its Phase I/IIa ENX-CL-05-001 clinical trial. This double-blind, randomized, placebo-controlled, multi-center study is evaluating its Allocetra™ therapy in patients with moderate-to-severe knee osteoarthritis. The related press release, dated August 14, 2025, is furnished as Exhibit 99.1.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: August 2025

Commission file number: 001-36578

ENLIVEX THERAPEUTICS LTD.

(Translation of registrant’s name into English)

14 Einstein Street, Nes Ziona, Israel 7403618

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

On August 14, 2025, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel, issued a press release announcing that it will host a webinar on Monday, August 18, 2025, at 8:00 AM Eastern Time to present and discuss 3-month topline results from the Phase IIa stage of its Phase I/IIa ENX-CL-05-001 trial, a double-blind, randomized, placebo-controlled multi-centered study evaluating Allocetra™ in patients with moderate-to-severe knee osteoarthritis. A copy of such press release is furnished as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.

Exhibit No.
99.1		Press Release issued by Enlivex Therapeutics Ltd. on August 14, 2025.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Enlivex Therapeutics Ltd.
	(Registrant)
	By:	/s/ Oren Hershkovitz
	Name:	Oren Hershkovitz
	Title:	Chief Executive Officer

Date: August 14, 2025

2

FAQ

What did Enlivex Therapeutics (ENLV) disclose in this Form 6-K?

Enlivex Therapeutics Ltd. disclosed that it will host a webinar to present and discuss 3‑month topline results from the Phase IIa stage of its Phase I/IIa ENX-CL-05-001 trial evaluating Allocetra™ in moderate-to-severe knee osteoarthritis.

When is Enlivex Therapeutics (ENLV) hosting the webinar on the Allocetra™ trial?

The company plans to host the webinar on Monday, August 18, 2025, at 8:00 Eastern Time to discuss 3‑month topline Phase IIa results from its ENX-CL-05-001 trial.

What clinical study is Enlivex (ENLV) discussing in the August 2025 webinar?

The webinar will cover 3‑month topline results from the Phase IIa stage of the Phase I/IIa ENX-CL-05-001 trial, a double-blind, randomized, placebo-controlled, multi-centered study evaluating Allocetra™ in patients with moderate-to-severe knee osteoarthritis.

What is Allocetra™ being evaluated for in Enlivex’s ENX-CL-05-001 trial?

Allocetra™ is being evaluated in a double-blind, randomized, placebo-controlled, multi-centered Phase I/IIa study for patients with moderate-to-severe knee osteoarthritis.

Where can investors find more details about Enlivex’s webinar announcement?

More details are provided in the press release issued by Enlivex Therapeutics Ltd. on August 14, 2025, which is furnished as Exhibit 99.1 to the Form 6-K.

Does this Form 6-K include the actual topline results for Enlivex (ENLV)?

No. The document states that Enlivex plans to present and discuss 3‑month topline Phase IIa results at a webinar and furnishes the related press release as Exhibit 99.1.